The Potential Impact of Substitutive Therapy With Intravenous Immunoglobulin on the Outcome of Heart Transplant Recipients With Infections

Carbone, J.; Sarmiento, E.; Palomo, Jesús; Fernàndez-Yáñez, J.; Muñóz, Patricia; Bouza, Emilio; Rodrı́guez-Molina, J.; Lanio, N.; Fernández‐Cruz, Eduardo

doi:10.1016/j.transproceed.2007.06.050

Cited by 36 publications

(35 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet, approximately 20% of SOT recipients who develop CDI have no preceding antimicrobial exposure (4), likely related to immune dysfunction in SOT. Impairments of humoral immunity may have the most significant impact on the control of C. difficile (4); in one study, the incidence of CDI in heart transplants decreased after the introduction of immunoglobulin posttransplant (6). Immunosuppressive medications alter the intestinal microbiota further contributing to dysbiosis and C. difficile overgrowth (7).…”

Section: Introductionmentioning

confidence: 99%

Fecal Microbiota Transplantation for Refractory Clostridium difficile Colitis in Solid Organ Transplant Recipients

Friedman‐Moraco

Mehta

Lyon

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) has been shown to be safe and efficacious in individuals with refractory Clostridium difficile . It has not been widely studied in individuals with immunosuppression due to concerns about infectious complications. We describe two solid organ transplant recipients, one lung and one renal, in this case report that both had resolution of their diarrhea caused by C. difficile after FMT. Both recipients required two FMTs to achieve resolution of their symptoms and neither had infectious complications. Immunosuppressed individuals are at high risk for acquisition of C. difficile and close monitoring for infectious complications after FMT is necessary, but should not preclude its use in patients with refractory disease due to C. difficile . Sequential FMT may be used to achieve cure in these patients with damaged microbiota from antibiotic use and immunosuppression.

show abstract

Section: Introductionmentioning

confidence: 99%

Fecal Microbiota Transplantation for Refractory Clostridium difficile Colitis in Solid Organ Transplant Recipients

Friedman‐Moraco

Mehta

Lyon

et al. 2014

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…26,27 IgG substitution use has been described in post-transplant IgG hypogammaglobulinemic heart transplant patients and is included in our institutional protocols. 28,29 Confirmation of IPRA requires demonstration of septate hyphae invading the prostatic tissue and isolation of Aspergillus in representative clinical samples. Hyphae morphology alone cannot differentiate Aspergillus from other more uncommon pathogens such as Scedosporium or Fusarium.…”

Section: Discussionmentioning

confidence: 99%

Prostatic Aspergillosis in a Heart Transplant Recipient: Case Report and Review

Valerio¹,

Fernàndez-Yáñez²,

Palomo³

et al. 2009

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…50 In a step further, several studies reported a decreased number of episodes of infections and rejection in patients with severe (<350 mg/dL) and moderate (300-500 mg/dL) hypoglobulinemia who received immunoglobulin preemptive therapy. [50][51][52][53] We recommend the adjunctive use of intravenous immunoglobulins (400 mg/kg) in heart transplant recipients with severe hypogammaglobulinemia.…”

Section: Treatmentmentioning

confidence: 99%

Adenovirus Infections in Heart Transplantation

Florescu¹,

Kwon

Dumitru

2013

Cardiology in Review

View full text Add to dashboard Cite

Adenovirus infections have been associated with significant morbidity and mortality in immunocompromised hosts. The clinical significance of adenovirus disease in heart transplantation is not well-defined; in particular, the significance of adenovirus identification in myocardium remains unclear. Although severe adenovirus disease has been described in heart transplant recipients, adenovirus infections seem to be more frequently associated with increased risk of adverse cardiac events, such as rejection, ventricular dysfunction, coronary vasculopathy, need for retransplantation, and graft loss because of death. Cidofovir is currently considered the standard of treatment for adenovirus disease not responding to reduction of immunosuppression.

show abstract

The Potential Impact of Substitutive Therapy With Intravenous Immunoglobulin on the Outcome of Heart Transplant Recipients With Infections

Cited by 36 publications

References 7 publications

Fecal Microbiota Transplantation for Refractory Clostridium difficile Colitis in Solid Organ Transplant Recipients

Fecal Microbiota Transplantation for Refractory Clostridium difficile Colitis in Solid Organ Transplant Recipients

Prostatic Aspergillosis in a Heart Transplant Recipient: Case Report and Review

Adenovirus Infections in Heart Transplantation

Contact Info

Product

Resources

About